Terapia sistêmica na doença HER2+ convertida em axila positiva pós-cirurgia e PET/CT vs TC no paciente metastático

Notas do episódio

Referências: 1. Weiss A, Martínez-Sáez O, Waks AG, Laws A, McGrath M, Tarantino P, Portnow L, Winer E, Rey M, Tapia M, Prat A, Partridge AH, Tolaney SM, Cejalvo JM, Mittendorf EA, King TA. Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts. Cancer. 2023 Mar 23. doi: 10.1002/cncr.34750. Epub ahead of print. PMID: 36951169. https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.34750 2. Vogsen, M., Naghavi-Behzad, M., Harbo, F.G. et al. 2-[18F]FDG-PET/CT is a better predictor of survival than conventional CT: a prospective study of response monitoring in metastatic breast cancer. Sci Rep 13, 5552 (2023). https://doi.org/10.1038/s41598-023-32727-w --